Gene symbol | MAGEA1 | Synonyms | CT1.1, MAGE1 | Type of gene | protein-coding |
Chromosome | X | Map location | Xq28 | dbXrefs | |
Description | MAGE family member A1 |
Gene symbol | MAGEA3 | Synonyms | CT1.3, HIP8, HYPD, MAGE3, MAGEA6 | Type of gene | protein-coding |
Chromosome | X | Map location | Xq28 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | MAGE family member A3 |
GTO ID | GTC0207 |
Trial ID | NCT02153905 |
Disease | Renal Carcinoma | Melanoma | Bladder Cancer | Breast Cancer | Cervical Cancer |
Altered gene | MAGE-A3|MAGE-A1 |
Therapeutic/Target gene | Target gene |
Therapy | TCR-T cell |
Treatment | MAGE-A1/A3 TCR-T cells |
HLA | HLA-A*01 |
Phase | Phase1|Phase2 |
Recruitment status | Terminated |
Title | A Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin |
Year | 2014 |
Country | United States |
Company sponsor | National Cancer Institute (NCI) |
Other ID(s) | 140110|14-C-0110 |
Vector information | |||||
|
Cohort1: dose level 1 | |||||||||||||||||
|
|||||||||||||||||
Cohort2: dose level 2 | |||||||||||||||||
|